AU2023221507A1 - Liquid botulinum toxin formulation and use thereof - Google Patents

Liquid botulinum toxin formulation and use thereof Download PDF

Info

Publication number
AU2023221507A1
AU2023221507A1 AU2023221507A AU2023221507A AU2023221507A1 AU 2023221507 A1 AU2023221507 A1 AU 2023221507A1 AU 2023221507 A AU2023221507 A AU 2023221507A AU 2023221507 A AU2023221507 A AU 2023221507A AU 2023221507 A1 AU2023221507 A1 AU 2023221507A1
Authority
AU
Australia
Prior art keywords
liquid formulation
chelating agent
serum albumin
human serum
botulinum toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023221507A
Other languages
English (en)
Inventor
Karl-Heinz Eisele
Klaus Fink
Claudia Jatzke
Katja KÜHBACH
Harold V. Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharma GmbH and Co KGaA
Original Assignee
Merz Pharma GmbH and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma GmbH and Co KGaA filed Critical Merz Pharma GmbH and Co KGaA
Publication of AU2023221507A1 publication Critical patent/AU2023221507A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
AU2023221507A 2022-02-15 2023-02-14 Liquid botulinum toxin formulation and use thereof Pending AU2023221507A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22156843 2022-02-15
EP22156843.9 2022-02-15
EP22183172 2022-07-05
EP22183172.0 2022-07-05
PCT/EP2023/053647 WO2023156389A1 (en) 2022-02-15 2023-02-14 Liquid botulinum toxin formulation and use thereof

Publications (1)

Publication Number Publication Date
AU2023221507A1 true AU2023221507A1 (en) 2024-08-08

Family

ID=85202119

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023221507A Pending AU2023221507A1 (en) 2022-02-15 2023-02-14 Liquid botulinum toxin formulation and use thereof

Country Status (13)

Country Link
US (1) US20250152682A1 (https=)
EP (1) EP4479023A1 (https=)
JP (1) JP2025504249A (https=)
KR (1) KR20240141340A (https=)
CN (1) CN119031902A (https=)
AR (1) AR128514A1 (https=)
AU (1) AU2023221507A1 (https=)
CA (1) CA3243238A1 (https=)
CO (1) CO2024010940A2 (https=)
IL (1) IL315004A (https=)
MX (1) MX2024009970A (https=)
TW (1) TW202348248A (https=)
WO (1) WO2023156389A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025228877A1 (en) 2024-04-29 2025-11-06 Merz Therapeutics GmbH Botulinum toxin for the preventive treatment of migraine
WO2026021713A1 (en) 2024-07-23 2026-01-29 Merz Therapeutics GmbH Uses of magnetic nerve stimulation associated with botulinum neurotoxin administration

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
JP2006045173A (ja) * 2004-08-09 2006-02-16 Hidetoshi Tsuchida 表面修飾血清アルブミン−金属ポルフィリン複合体、およびそれを含有する酸素輸液
PT2271670E (pt) 2008-03-14 2014-11-28 Allergan Inc Ensaio imunobaseado da atividade do serotipo a da toxina botulínica
CA2766649C (en) * 2009-06-24 2016-08-23 Charles N.S. Soparkar Zinc supplementation to increase responsiveness to metalloprotease therapy
ES2653249T3 (es) 2011-09-29 2018-02-06 Cellsnap, Llc Composiciones y métodos para ensayos de toxigenicidad
AU2014301116B2 (en) 2013-06-28 2019-11-14 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of Neurotoxin polypeptides in cells
PL3463432T3 (pl) * 2016-05-27 2021-04-19 Ipsen Biopharm Limited Ciekła formulacja neurotoksyny stabilizowana tryptofanem lub tyrozyną

Also Published As

Publication number Publication date
MX2024009970A (es) 2024-09-18
US20250152682A1 (en) 2025-05-15
AR128514A1 (es) 2024-05-15
KR20240141340A (ko) 2024-09-26
TW202348248A (zh) 2023-12-16
CN119031902A (zh) 2024-11-26
JP2025504249A (ja) 2025-02-06
WO2023156389A1 (en) 2023-08-24
CA3243238A1 (en) 2023-08-24
EP4479023A1 (en) 2024-12-25
IL315004A (en) 2024-10-01
CO2024010940A2 (es) 2024-09-19

Similar Documents

Publication Publication Date Title
EP4479023A1 (en) Liquid botulinum toxin formulation and use thereof
JP2021193103A (ja) ボツリヌス神経毒素を得るためのプロセスおよびシステム
AU2006299366B2 (en) Non-protein stabilized clostridial toxin pharmaceutical compositions
SI20566A (sl) Stabilne tekoče oblike botulinusovega toksina
JPS6214271B2 (https=)
WO2023156385A1 (en) Liquid botulinum toxin formulation and use thereof
CN103211774A (zh) 一种注射用甲磺酸加贝酯组合物及其制备方法
CN114177273B (zh) 一种含有神经毒素的液体制剂及其制备方法
HK40113170A (zh) 液体肉毒杆菌毒素制剂及其用途
CN101904862B (zh) 注射用水溶性维生素组合物冻干制剂
AU2024322347A1 (en) Liquid botulinum toxin formulation and use thereof
ES2993230A2 (es) Composiciones de la neurotoxina de Clostridium botulinum serotipo A
KR20260052068A (ko) 보툴리눔 독소 액체 제형 및 그 용도
HK40116988A (zh) 液体肉毒杆菌毒素制剂及其用途
CN102697742B (zh) 注射用盐酸头孢唑兰的制备工艺
AU2012202088B2 (en) Non-protein stabilized clostridial toxin pharmaceutical compositions
CN110314132B (zh) 一种门冬氨酸鸟氨酸注射液及其制备方法
AU2016204034A1 (en) Non-protein stabilized clostridial toxin pharmaceutical compositions
CN118829726A (zh) 包含胶原酶、钙、组氨酸及甘氨酸的组合物及胶原酶的稳定化方法
ES2992717A2 (es) Variantes de la secuencia de la neurotoxina de Clostridium botulinum serotipo A (BoNT/A)
GB2700167A (en) Clostridium botlinum neurotoxin serotype a compositions and improved drying processes
BR112019003770B1 (pt) Formulação líquida que contém toxina botulínica e agente de estabilização, e método de preparação para a mesma